66021-75-8

Basic information

• Product Name: Benzene, [(2-azidoethoxy)methyl]-
• CAS NO: 66021-75-8
• Molecular Formula: C9H11N3O
• Molecular Weight: 177.206
• Mol File: 66021-75-8.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzene, [(2-azidoethoxy)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, [(2-azidoethoxy)methyl]-(66021-75-8)
• EPA Substance Registry System: Benzene, [(2-azidoethoxy)methyl]-(66021-75-8)

Safety Data

• Hazardous Substances Data: 66021-75-8(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 107-21-1 ethylene glycol 
• 1462-37-9 bromoethyl-2-benzyl ether 
• 622-08-2 2-Benzyloxyethanol 
• 4981-83-3 2-(Benzyloxy)ethyl p-toluenesulfonate 
• 17229-17-3 benzyl 2-chloroethyl ether 
• 58841-52-4 2-(benzyloxy)ethyl methanesulfonate 

Downstream Products

• 1448552-44-0 C₃₅H₃₉N₅O₄S 
• 3394-32-9 2-phenyloxazolidine 
• 634925-24-9 tert-butyl (2-(benzyloxy)ethyl)carbamate 
• 1246847-81-3 C₁₈H₁₉N₃O₂ 
• 200400-72-2 N-<2-(benzyloxy)ethyl>-2-<4-(3-pyridylcarbonyl)phenyl>-4-oxazolecarboxamide 
• 38336-04-8 O-benzylethanolamine 

Relevant articles and documents

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1

A series of non-peptide inhibitors targeting the polo-box domain (PBD) of polo-like kinase 1 (Plk1) was designed based on the potent and selective minimal tripeptide Plk1 PBD inhibitor. Seven compounds were designed, synthesized and evaluated for fluorescence polarization (FP) assay. The most promising compound 10 bound to Plk1 PBD with IC50 of 3.37 μM and had no binding to Plk2 PBD or Plk3 PBD at 100 μM. Molecular docking study was performed and possible binding mode was proposed. MM/GBSA binding free energy calculation were in agreement with the observed experimental results. These novel non-peptide selective Plk1 PBD inhibitors provided new lead compounds for further optimization.

Use of triazole-ring formation to attach a Ru/TsDPEN complex for asymmetric transfer hydrogenation to a soluble polymer

The cycloaddition of a chiral ligand containing a terminal alkyne to a soluble polymer containing an azide provides a convenient means for the attachment of an asymmetric transfer hydrogenation catalyst to a soluble polymer support. Using these ligands in complexes with Ru(II), gave good results in terms of conversion and enantioselectivity (up to 95% ee) in ketone reduction reactions.

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted ω-phenyl-ω-(3-pyridyl)alkenoic acid derivatives and related compounds

A novel series of oxazolecarboxamide-substituted ω-phenyl-ω-(3- pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA2 receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4- [4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept- 6-enoic acid (14) with K(d) = 9.9 ± 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 ± 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, 'shunt' effect to elevate PGI2 level, and absence of agonist activity.